Inventor · disambiguated record
David Din Belle
Also filed as: DIN BELLE DAVID
7 granted patents·13 pending applications·9 citations·filing 2008–2024
78Inventor score
Top patents by PatentIndex Score
20 records- 0191US11098032B2Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitorsORION CORP·Filed 2020·Granted Aug 24, 2021·3 cites·11 claims
- 0287US10717726B2Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitorsORION CORP·Filed 2017·Granted Jul 21, 2020·3 cites·35 claims
- 0381US2024308989A1Pyran derivatives as cyp11a1 (cytochrome p450 monooxygenase 11a1) inhibitorsORION CORP·Filed 2024·Application pending·0 cites
- 0470US12030871B2Pyran dervatives as CYP11A1 (cytochrome P450 monooxygenase 11A1) inhibitorsORION CORP·Filed 2021·Granted Jul 9, 2024·0 cites·24 claims
- 0569US2022047540A1Catechol o-methyltransferase activity inhibiting compoundsORION CORP·Filed 2021·Application pending·0 cites
- 0668US8809536B22,3-dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseasesORION CORP·Filed 2014·Granted Aug 19, 2014·1 cites·11 claims
- 0767US8492549B22,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous systeme diseasesDIN BELLE DAVID·Filed 2008·Granted Jul 23, 2013·2 cites·34 claims
- 0865US2020352898A1Catechol o-methyltransferase activity inhibiting compoundsORION CORP·Filed 2020·Application pending·0 cites
- 0959US2020009103A1Catechol o-methyltransferase activity inhibiting compoundsORION CORP·Filed 2019·Application pending·0 cites
- 1059US2025011285A1Cyp11a1 inhibitorsORION CORP·Filed 2022·Application pending·0 cites
- 1158US2019029990A1Catechol o-methyltransferase activity inhibiting compoundsORION CORP·Filed 2018·Application pending·0 cites
- 1255US9458128B2Catechol O-methyltransferase activity inhibiting compoundsORION CORP·Filed 2013·Granted Oct 4, 2016·0 cites·52 claims
- 1355US2025257054A1Salt forms of a 4h-pyran-4-one structured cyp11 a1 inhibitorORION CORP·Filed 2022·Application pending·0 cites
- 1455US2024246908A1Tead inhibitorsORION CORP·Filed 2022·Application pending·0 cites
- 1554US2024124431A12,3-dihydro-4h-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as cyp11a1 inhibitors for the treatment of prostate cancerORION CORP·Filed 2021·Application pending·0 cites
- 1653US2017165219A1Catechol o-methyltransferase activity inhibiting compoundsORION CORP·Filed 2016·Application pending·0 cites
- 1752US8697723B22,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseasesORION CORP·Filed 2013·Granted Apr 15, 2014·0 cites·2 claims
- 1849US2023192677A1Cyp11a1 inhibitorsORION CORP·Filed 2021·Application pending·0 cites
- 1945US2021347728A14,5-dihydroxy-2-(4-methylbenzyl)isophthalonitrile solvates and crystalline forms thereofORION CORP·Filed 2019·Application pending·0 cites
- 2044US2011262352A1Aryl piperazine and their use as alpha2c antagonistsDIN BELLE DAVID·Filed 2009·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →